FDA extends Leqembi Iqlik review period to August 24

May 8, 2026 2:48 AM

The U.S. Food and Drug Administration has extended the review period for Eisai's supplemental Biologics License Application for Leqembi Iqlik ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found